📊 LYRA Key Takeaways
Is Lyra Therapeutics, Inc. (LYRA) a Good Investment?
Lyra Therapeutics faces severe financial distress with negative stockholders' equity of -$10.7M, indicating the company is technically insolvent. Revenue has collapsed 74% YoY to just $398K while operating losses remain substantial at -$31M, demonstrating a complete absence of viable business operations or revenue generation.
Lyra Therapeutics' fundamentals are extremely weak: revenue is minimal and down 74.1% year over year, while operating and net losses remain far larger than the company’s revenue base. The balance sheet is stressed with negative stockholders' equity and annual operating cash burn of roughly $28.9M against only $15.9M of cash, implying a high likelihood of further financing pressure unless the business materially improves.
Why Buy Lyra Therapeutics, Inc. Stock? LYRA Key Strengths
- Maintains $15.9M in cash reserves providing short-term runway
- Current ratio of 1.71x indicates adequate short-term liquidity relative to current liabilities
- Limited insider selling activity with only 2 Form 4 filings in last 90 days suggests management confidence or constraint
- Current and quick ratios of 1.71x indicate short-term liabilities are still covered at the latest reporting date
- Cash and equivalents of $15.89M provide a near-term liquidity buffer
- Capital expenditure is very low, which limits additional fixed-investment demands
LYRA Stock Risks: Lyra Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$10.7M indicates technical insolvency and existential financial distress
- Revenue collapse of 74% YoY combined with -$31M operating loss demonstrates business model failure
- Negative operating cash flow of -$28.9M with cash burn rate unsustainable even with current cash reserves; company has approximately 6.6 months of runway
- Total liabilities exceed total assets by $10.7M creating structural balance sheet insolvency
- Extreme operating margin of -7794.5% and net margin of -7266.1% indicate zero path to profitability
- Revenue base is extremely small and declined 74.1% year over year, indicating weak growth quality and poor commercial traction
- Operating loss of $31.02M and free cash flow of -$28.98M show the business is far from self-sustaining
- Negative stockholders equity of -$10.72M signals balance-sheet deterioration and raises recapitalization risk
Key Metrics to Watch
- Monthly cash burn rate and estimated cash runway
- Revenue trends for stabilization or continued deterioration
- Debt restructuring announcements or covenant violations
- Insider transactions indicating confidence or exit activity
- Quarterly operating cash flow for persistence of negative trends
- Quarterly cash balance and operating cash burn runway
- Revenue trend and progress toward materially reducing operating losses
Lyra Therapeutics, Inc. (LYRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Lyra Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LYRA Profit Margin, ROE & Profitability Analysis
LYRA vs Healthcare Sector: How Lyra Therapeutics, Inc. Compares
How Lyra Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lyra Therapeutics, Inc. Stock Overvalued? LYRA Valuation Analysis 2026
Based on fundamental analysis, Lyra Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lyra Therapeutics, Inc. Balance Sheet: LYRA Debt, Cash & Liquidity
LYRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lyra Therapeutics, Inc.'s revenue has grown significantly by 438% over the 5-year period, indicating strong business expansion. The most recent EPS of $-71.75 indicates the company is currently unprofitable.
LYRA Revenue Growth, EPS Growth & YoY Performance
LYRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $25.0K | -$6.0M | $-3.38 |
| Q2 2025 | $183.0K | -$7.4M | $-5.51 |
| Q1 2025 | $183.0K | -$8.5M | $-0.13 |
| Q3 2024 | $195.0K | -$11.9M | $-0.18 |
| Q2 2024 | $458.0K | -$15.6M | $-0.36 |
| Q1 2024 | $410.0K | -$16.3M | $-0.35 |
| Q3 2023 | $359.0K | -$11.9M | $-0.27 |
| Q2 2023 | $458.0K | -$11.9M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lyra Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
LYRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lyra Therapeutics, Inc. (CIK: 0001327273)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LYRA
What is the AI rating for LYRA?
Lyra Therapeutics, Inc. (LYRA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LYRA's key strengths?
Claude: Maintains $15.9M in cash reserves providing short-term runway. Current ratio of 1.71x indicates adequate short-term liquidity relative to current liabilities. ChatGPT: Current and quick ratios of 1.71x indicate short-term liabilities are still covered at the latest reporting date. Cash and equivalents of $15.89M provide a near-term liquidity buffer.
What are the risks of investing in LYRA?
Claude: Negative stockholders' equity of -$10.7M indicates technical insolvency and existential financial distress. Revenue collapse of 74% YoY combined with -$31M operating loss demonstrates business model failure. ChatGPT: Revenue base is extremely small and declined 74.1% year over year, indicating weak growth quality and poor commercial traction. Operating loss of $31.02M and free cash flow of -$28.98M show the business is far from self-sustaining.
What is LYRA's revenue and growth?
Lyra Therapeutics, Inc. reported revenue of $398.0K.
Does LYRA pay dividends?
Lyra Therapeutics, Inc. does not currently pay dividends.
Where can I find LYRA SEC filings?
Official SEC filings for Lyra Therapeutics, Inc. (CIK: 0001327273) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LYRA's EPS?
Lyra Therapeutics, Inc. has a diluted EPS of $-18.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LYRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lyra Therapeutics, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LYRA stock overvalued or undervalued?
Valuation metrics for LYRA: ROE of N/A (sector avg: 15%), net margin of -7,266.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LYRA stock in 2026?
Our dual AI analysis gives Lyra Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LYRA's free cash flow?
Lyra Therapeutics, Inc.'s operating cash flow is $-28.9M, with capital expenditures of $116.0K. FCF margin is -7,280.2%.
How does LYRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7,266.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.71 (avg: 2).